Category: Musculoskeletal

Heel fat pad atrophy is an increasingly recognised cause of plantar heel pain, especially in older or high‑impact populations, and is frequently misdiagnosed as plantar fasciopathy. It involves structural and functional failure of the calcaneal fat pad, resulting in reduced shock absorption, focal overloading of the calcaneus, and characteristic bruised, central heel pain with weightbearing.

Anatomy and biomechanics of the heel fat pad

The plantar calcaneal fat pad (corpus adiposum) is a specialised fibro‑adipose structure that overlies the inferior surface of the calcaneus. It is organised into elastic fat chambers separated by fibrous septa that anchor to the periosteum, designed to resist shear and dissipate vertical ground reaction forces during gait. In a healthy adult, heel pad thickness is typically around 1–2 cm, with ultrasound studies reporting unloaded thickness close to 18–20 mm and significant but controlled compressibility under load. During walking, the heel can be exposed to forces of approximately 110% of body weight, rising to around 200% during running, which the fat pad normally attenuates. This mechanical role explains why subtle structural change can produce disproportionate symptoms.

Pathophysiology and aetiology

Heel fat pad atrophy reflects thinning, fragmentation, or displacement of the corpus adiposum accompanied by loss of elasticity and hydration. Micromechanical failure of the fibrous septa is thought to reduce structural integrity, impairing shock absorption and allowing higher peak plantar pressures directly over the calcaneus. Over time, repetitive high‑impact loading, such as running or jumping, and prolonged standing on hard surfaces drive cumulative microtrauma and wear, particularly when combined with inadequate footwear or barefoot loading on rigid substrates.

Multiple intrinsic and extrinsic factors contribute. Ageing leads to reduced collagen elasticity, loss of soft‑tissue moisture, and thinning or displacement of the fat pad, making heel fat pad syndrome more prevalent in older adults. Biomechanical factors, including altered arch alignment, high arches, and abnormal gait patterns, shift load toward the posterior calcaneus and increase local stress. A history of corticosteroid injection into or near the heel has been associated with fat pad breakdown, presumably via catabolic effects on collagen and adipose tissue. Systemic factors such as obesity and certain medical conditions further compromise tissue integrity and may accelerate thinning. Less commonly, acute trauma or a single episode of excessive heel strike can precipitate symptomatic structural failure.

Clinical presentation and differential diagnosis

Clinically, patients typically describe a deep, dull, “bruised” pain centred under the heel that is provoked by weightbearing and worsens on hard surfaces or when walking barefoot. Standing or walking for prolonged periods aggravates symptoms, whereas non‑weightbearing usually provides rapid relief. On examination, there is focal tenderness beneath the posterior‑central calcaneus, often slightly lateral to the midline, corresponding to the main weightbearing point at heel strike. The pad may feel thinned or less resilient on palpation compared to the contralateral side, and compressive testing may reproduce pain.

Differentiating heel fat pad atrophy from plantar fasciopathy is clinically important, as management priorities differ. Plantar fasciitis usually presents with medial calcaneal and proximal fascial tenderness and pronounced “first‑step” pain after rest, whereas fat pad pain is more central/posterior, often maximal during prolonged standing or impact and particularly severe when barefoot on firm ground. Radiology and ultrasound can assist: imaging in heel fat pad syndrome may demonstrate reduced fat pad thickness, altered echotexture, septal defects, fibrosis, or oedema within or around the pad, whereas plantar fasciopathy shows fascial thickening and entheseal changes. A scoping review suggests heel fat pad syndrome may be the second most common cause of plantar heel pain, yet is frequently overlooked or conflated with plantar fasciopathy in the literature and in practice.

Investigations

Although heel fat pad atrophy is primarily a clinical diagnosis, imaging can provide objective corroboration and help exclude other pathology. Ultrasound offers a practical method to quantify heel pad thickness in unloaded and loaded states and to assess compressibility, with studies reporting abnormal thinning and altered compressibility indices in symptomatic patients. MRI can demonstrate changes such as focal atrophy, fibrosis, oedema, and septal defects, alongside assessment of surrounding soft tissues and bone marrow. Radiographs may be useful to assess calcaneal spurs or other bony pathology but are less informative regarding fat pad quality. Objective measurement can be valuable in tracking progression and response to interventions in both clinical and research settings.

Conservative management

Management is initially conservative and centres on reducing peak plantar pressures while optimising overall foot biomechanics. Activity modification is foundational: patients are advised to reduce or temporarily cease high‑impact activities such as distance running and court sports, substituting with lower‑impact exercise where possible. Footwear education is crucial, emphasising supportive shoes with firm heel counters, appropriate arch support, and adequate heel cushioning; walking barefoot or in thin‑soled footwear on hard surfaces is discouraged. External devices—including cushioned socks, silicone or gel heel cups, and custom or semi‑custom insoles—aim to increase cushioning and, importantly, to contain and centralise the fat pad under the calcaneus.

Clinical taping techniques can be used to “cup” and reposition the pad beneath the heel, providing symptomatic relief and serving as a predictor of orthotic response. Physiotherapy or podiatry‑led rehabilitation often includes strengthening of intrinsic and extrinsic foot and ankle musculature, improving load sharing and dynamic stability, as well as targeted mobilisation of the rearfoot, talocrural joint, and plantar fascia to restore normal motion patterns. Adjunctive measures, such as short periods of icing and judicious use of oral or topical non‑steroidal anti‑inflammatories, may assist during acute exacerbations, although they do not address the underlying structural deficit. Importantly, repeated corticosteroid injection into the heel should be avoided in this population because of its association with further fat pad compromise.

Emerging interventional approaches and evidence gaps

For patients who remain significantly symptomatic despite optimised conservative care, several interventional strategies have been explored, though the evidence base remains limited. These include injectable fillers and heel fat pad augmentation via autologous fat grafting, which aim to restore volume and shock‑absorbing capacity. Clinical trial protocols investigating autologous fat transfer suggest that improving plantar cushioning may reduce peak plantar pressures, potentially lowering the risk of ulceration in high‑risk groups such as individuals with diabetes and bony prominence. Early case series and small studies report imaging‑confirmed changes in fat pad morphology, including atrophy, fibrosis, and oedema, but there remains a “glaring absence” of robust controlled trials evaluating the long‑term efficacy and durability of commonly used conservative and surgical interventions.

Consequently, current best practice emphasises accurate diagnosis, comprehensive mechanical off‑loading, and optimisation of global foot function, while recognising that definitive regenerative solutions are still under investigation. From a clinical perspective, heel fat pad atrophy underscores the importance of viewing plantar heel pain as a heterogeneous symptom complex rather than a monolithic “plantar fasciitis” entity, demanding careful localisation of pain, biomechanical assessment, and tailored intervention.

Rigid carbon plates are a key non‑operative option for reducing first metatarsophalangeal joint (1st MTPJ) pain and improving function in patients with hallux rigidus by limiting painful dorsiflexion while preserving overall gait efficiency. Their use is supported by clinical studies on rigid and carbon‑based insoles, as well as growing clinical experience and commercial device design focused on targeted forefoot motion control.

Pathophysiology of hallux rigidus

Hallux rigidus is a degenerative arthropathy of the 1st MTPJ characterised by progressive cartilage loss, dorsal osteophyte formation, and reduced sagittal plane range of motion, particularly dorsiflexion. The loss of joint congruency and osteophyte impingement elevates joint reaction forces during propulsion, producing pain, stiffness, and altered push‑off mechanics.

As dorsiflexion becomes limited and painful, patients commonly compensate by externally rotating the foot, transferring load laterally to lesser metatarsal heads, or shortening step length, which can lead to secondary metatarsalgia, midfoot overload, and reduced walking speed. Conservative interventions therefore aim to reduce painful dorsiflexion moments at the 1st MTPJ while maintaining sufficient forefoot stability for efficient gait

Rationale for rigid carbon plates

Rigid orthoses have long been used to “splint” the first ray and limit 1st MTPJ motion as a primary strategy in conservative management of hallux rigidus. A systematic review of non‑operative care reports that footwear modifications and rigid custom insoles are effective in roughly half of patients, supporting their role as first‑line therapy.

Carbon fibre is particularly suited to this task because it offers very high stiffness at minimal thickness and weight, allowing substantial motion restriction with relatively low bulk. By stiffening the forefoot region of the shoe, carbon plates reduce bending at the ball of the foot so that the big toe joint does not need to dorsiflex as much during terminal stance, thereby decreasing joint loading and pain.

Design characteristics of carbon plates

Rigid carbon plates for hallux rigidus are usually thin (around 1.0–1.2 mm) and flat or slightly contoured, with minimal flex across the metatarsal heads. Their stiffness is achieved using high‑strength carbon (often combined with glass fibres) embedded in a polymer matrix, producing a durable, fatigue‑resistant structure that tolerates repetitive forefoot loading.

Two main geometries are commonly employed:

• Morton’s extension plates: extend under the hallux and first metatarsal, allowing more normal motion of the lateral metatarsophalangeal joints while specifically splinting the first ray.carboneaze+1
• Full‑width forefoot plates: span the entire forefoot, limiting motion at both the 1st MTPJ and lesser MTPJs and creating a more global rocker effect.

Choice of design is typically dictated by whether isolated first‑ray control is desired or whether broader forefoot immobilisation and rocker function are clinically advantageous.

Clinical evidence for carbon‑based insoles

Although many traditional devices used polypropylene or other rigid plastics, carbon fibre has increasingly been adopted as a base material for rigid 1st ray splinting orthoses. A randomized controlled trial comparing flexible carbon fibre insoles with a rigid Morton’s extension in patients with unilateral 1st MTPJ arthritis found that flexible carbon insoles produced significantly greater reductions in pain interference and pain intensity scores at 6 and 12 weeks, with higher comfort and better compliance.

Specifically, the flexible carbon group demonstrated larger median improvements in PROMIS pain interference and pain intensity scales, while the more rigid Morton’s extension did not achieve similar gains despite also restricting motion. The authors concluded that carbon‑based insoles which balance mechanical shielding with some preserved motion may provide superior symptom relief and patient adherence compared with very rigid orthoses.

Beyond this trial, a broader review of conservative hallux rigidus care notes that custom insoles fabricated from rigid materials, including carbon fibre, reduce symptoms in a substantial proportion of patients and carry a moderate level of evidence within an evidence‑based framework. Emerging work in related forefoot and midfoot pathologies also suggests that full‑length carbon insoles can reduce forefoot loading and alter muscle activation patterns in ways that may support pain reduction and gait efficiency.

Mechanisms of symptom relief

Rigid carbon plates treat hallux rigidus primarily through mechanical modification of the 1st MTPJ environment:

• Motion restriction: By limiting dorsiflexion at the 1st MTPJ, plates decrease peak articular cartilage stress and dorsal osteophyte impingement during propulsion.
• Load redistribution: The stiffened forefoot encourages a more rocker‑like gait, shifting load proximally and to adjacent structures rather than concentrating it at the arthritic joint.
• Capsular protection: In conditions such as turf toe and big‑toe arthritis, carbon plates protect the joint capsule from excessive dorsiflexion and repetitive microtrauma.

These mechanical effects collectively reduce pain, dampen inflammatory flares, and may slow progression of degenerative change by limiting repeated high‑stress motion at the affected joint.

Integration with footwear and orthoses

Successful use of rigid carbon plates depends heavily on shoe compatibility and integration with existing orthotic therapy. Many clinicians either place the plate directly under the insole in a suitable shoe, or incorporate it into a custom device to avoid excess bulk and maintain foot position control. Full‑length plates often work best in footwear with adequate depth and a relatively stiff outsole, further enhancing the rocker function created by the plate.

Layering a carbon plate beneath a functional orthotic can be particularly useful in hallux rigidus, with the plate restricting painful toe motion while the orthosis addresses rearfoot and midfoot mechanics and redistributes plantar pressures. However, excessive stack height from combining OTC inserts with separate plates can compromise fit and comfort, so careful device selection and shoe testing are important.

Advantages and limitations

Rigid carbon plates offer several practical advantages in managing hallux rigidus:

• High stiffness with low profile and weight, improving shoe fit compared with many traditional rigid insoles.
• Reversible, non‑invasive intervention compatible with other conservative measures such as NSAIDs, intra‑articular injections, and physiotherapy.
• Versatility in design (Morton’s extension vs full‑width) to tailor motion restriction to the individual’s pathology and activity demands.

Conversely, limitations include potential discomfort from excessive rigidity, difficulty fitting plates into fashion or low‑volume footwear, and patient reluctance to accept changes in shoe feel or forefoot rocker mechanics. Over‑restriction of forefoot motion may transfer stress to proximal joints or lesser MTPJs, and plates may not adequately control pain in advanced cases where surgical options such as cheilectomy, arthrodesis, or arthroplasty are more appropriate.

Place in overall management

Within the broader conservative algorithm for hallux rigidus—alongside pharmacologic therapy, intra‑articular injections, activity modification, and footwear changes—rigid carbon plates occupy a central role as a mechanical pain‑relief strategy that can delay or obviate surgery for many patients. Evidence indicates that about half of patients achieve meaningful symptom control with such conservative measures, justifying early and systematic use of these devices.

Contemporary research comparing rigid Morton’s extensions with flexible carbon fibre insoles suggests that optimal plate design for hallux rigidus may require a nuanced balance between sufficient rigidity to shield the joint and enough flexibility to preserve comfort and normal mechanics. For clinicians and patients, rigid and semi‑rigid carbon plates therefore represent a valuable, adaptable tool in the non‑operative management of hallux rigidus, particularly when carefully matched to footwear, orthotic strategy, and the individual’s functional goals.

Hallux rigidus is a degenerative arthritis of the first metatarsophalangeal (MTP) joint that leads to pain and progressive loss of dorsiflexion of the hallux, ultimately impairing gait and limiting activities that require push‑off. Treatment revolves around symptom relief, preservation of joint motion where possible, and restoration of function, using a stepwise approach from conservative care to surgery depending on disease severity, patient demands, and radiographic changes.

Principles and goals of treatment

The primary goals of treating hallux rigidus are to relieve pain, maintain or improve range of motion, and allow patients to walk and perform daily activities without significant limitation. Management must be individualized by considering the clinical stage (e.g. mild, moderate, or advanced arthritis), alignment of the first ray, patient age, activity level, and expectations regarding joint motion. In early stages, joint‑preserving strategies are typically preferred, whereas in end‑stage disease, procedures that sacrifice motion in exchange for reliable pain relief, such as arthrodesis, are often indicated.

Conservative management

Non‑operative treatment is recommended as first‑line management and can provide meaningful relief in approximately half of patients, particularly those with mild to moderate disease. Pharmacological measures include non‑steroidal anti‑inflammatory drugs (NSAIDs) to reduce synovitis and pain, although these rarely provide complete or lasting symptom control when used alone. Intra‑articular corticosteroid injections can produce short‑term pain relief—often on the order of weeks to a few months—with diminishing returns in more advanced grades, and intra‑articular hyaluronic acid has demonstrated a reduction in pain and improved function several months after injection in some series.

Footwear modification and orthoses represent key elements of conservative care. Stiff‑soled shoes, rocker‑bottom soles, and shoes with a higher toe box limit painful dorsiflexion at the first MTP joint and reduce pressure over dorsal osteophytes. Custom insoles or orthotics can offload the first MTP joint, support the medial longitudinal arch, and sometimes incorporate a Morton’s extension or carbon fiber plate to further reduce joint motion during push‑off. Collectively, footwear changes, insoles, and injections are among the most effective conservative strategies according to evidence‑based reviews, with moderate‑grade recommendations.

Physical and manual therapy approaches, while supported by relatively low‑level evidence, aim to optimize joint mechanics and muscular support. Interventions may include great toe mobilization, long‑axis traction of the MTP joint, mobilization of the sesamoids, stretching of capsular and tendon structures, and strengthening of the flexor hallucis longus and intrinsic foot muscles to improve the pulley mechanism and dynamic stabilization. Dynamic splinting to encourage first MTP extension has been reported to significantly increase active range of motion post‑operatively and could theoretically reduce progression from hallux limitus to rigidus, though robust randomized data are limited. Overall, conservative programs are best viewed as comprehensive packages that combine medication, injections, footwear modification, and targeted rehabilitation rather than single isolated modalities.

Joint‑sparing surgical options

When conservative measures fail, and especially in grades I–III disease where some dorsiflexion remains and joint surfaces are not completely destroyed, joint‑sparing operations are considered. The most established of these is cheilectomy, which consists of resecting dorsal osteophytes and a portion of the dorsal metatarsal head to improve dorsiflexion and reduce impingement. For early stages, cheilectomy alone has demonstrated excellent pain relief and functional outcomes, and even in some grade III cases, series have shown substantial improvement in visual analogue scale pain scores with low revision rates.

Cheilectomy can be combined with proximal phalanx osteotomy, such as a Moberg dorsal closing‑wedge osteotomy, to further increase dorsiflexion by shifting the arc of motion. In a cohort of high‑grade hallux rigidus, the combination of cheilectomy and Moberg osteotomy led to improved dorsiflexion, high patient satisfaction, and a low conversion rate to arthrodesis at mid‑term follow‑up, suggesting this is a reasonable option for active patients with residual motion pre‑operatively. Arthroscopic techniques allow debridement and dorsal cheilectomy through small portals and have been described mainly for grade I–II disease, offering potential benefits in terms of soft‑tissue preservation and recovery, though long‑term outcome data remain limited.

Interpositional arthroplasty is another joint‑sparing strategy mainly reserved for moderate to severe hallux rigidus in patients who strongly wish to preserve motion. Classic procedures such as Keller resection arthroplasty remove a portion of the base of the proximal phalanx, often combined with soft‑tissue interposition, but excessive resection can lead to toe weakening, shortening, and transfer metatarsalgia. Modern interpositional techniques may use capsular flaps, tendon graft, or synthetic materials as spacers to maintain joint space and allow painless motion, but outcomes can be more variable and less predictable than arthrodesis. Synthetic cartilage implants, such as polyvinyl alcohol hydrogel spacers, have shown short‑term results comparable to arthrodesis in terms of pain and function at around two years, with the advantage of preserving motion and a reported failure rate near 10%, though longer‑term durability is still under investigation.

Joint‑sacrificing procedures

In end‑stage hallux rigidus with severe cartilage loss, large osteophytes, and minimal remaining motion, joint‑sacrificing procedures are most commonly used. Arthrodesis of the first MTP joint is widely regarded as the gold standard for advanced disease because it reliably eliminates arthritic pain and provides a stable, plantigrade toe for push‑off. The procedure involves removal of the residual cartilage, preparation of subchondral bone, and fusion of the proximal phalanx to the metatarsal using screws and/or plates, with union rates typically high and long‑term satisfaction favorable. The trade‑off is permanent loss of first MTP motion, which can limit certain activities (e.g. kneeling, sprinting, high‑heeled shoes), but many patients adapt well with proper alignment of the fusion.

Implant arthroplasty, using metallic or silastic prostheses, aims to maintain joint motion while resurfacing arthritic surfaces. However, concerns exist about implant loosening, subsidence, and revision complexity over time, and evidence has not consistently shown superiority to arthrodesis in terms of pain relief and durability. For low‑demand or elderly patients reluctant to accept a fusion, implant arthroplasty or interpositional arthroplasty may still be considered, but careful counselling regarding risks, potential for failure, and need for eventual conversion to arthrodesis is essential.

Treatment selection and future directions

Choosing among the available treatments requires a structured assessment that integrates clinical staging, radiographic findings, and patient‑specific goals. In practice, early disease is often managed with a combination of footwear modification, orthoses, NSAIDs, injections, and possibly manual therapy, progressing to cheilectomy (with or without proximal phalanx osteotomy) if symptoms persist. For intermediate disease in active individuals with some preserved motion, extended cheilectomy, Moberg osteotomy, or interpositional/synthetic cartilage arthroplasty may be appropriate, while advanced cases with near‑complete cartilage loss are usually best served by first MTP arthrodesis.

Emerging options such as biologic injections (platelet‑rich plasma, bone marrow aspirate) and novel implant materials are being explored, but current evidence is insufficient to draw firm conclusions about their long‑term efficacy in hallux rigidus. High‑quality randomized controlled trials are still needed, particularly in the domain of physiotherapy and manual therapy, to clarify which conservative protocols offer the greatest benefit. For now, a graded, evidence‑informed approach that starts with conservative measures and progresses to well‑selected surgical procedures offers the best chance of restoring pain‑free function for patients with this common and disabling condition.

Hammer toes are a common forefoot deformity in which one or more lesser toes bend at the middle joint, producing pain, corns, and difficulty with footwear. Treatment focuses first on relieving symptoms and preventing progression with conservative measures, and only then on corrective surgery if deformity and pain persist.

Goals of treatment

Management of hammer toes aims to:

• Reduce pain and pressure from shoes and ground contact.
• Correct or control the deforming forces (muscle imbalance, tight tendons, poor footwear).
• Prevent secondary problems such as corns, calluses, ulceration, and difficulty walking.
• Straighten the toe and restore function when possible, particularly with surgery in rigid cases.

The choice between non‑surgical and surgical treatment depends mainly on whether the toe is still flexible, the intensity of pain, and the impact on daily activities.

Conservative (non‑surgical) treatment

Non‑surgical treatment is the first line for flexible or mildly symptomatic hammer toes and often gives substantial relief.

1. Footwear modification
   • Patients are advised to avoid tight, narrow, and high‑heeled shoes that crowd the toes and increase pressure on the bent joint.
   • Recommended shoes have a wide, deep toe box and low heels, and are about half a size longer than the longest toe so that there is space for the deformity and any protective padding.
2. Padding, cushioning, and taping
   • Soft pads, sleeves, or cushioning over the prominent joint redistribute pressure and reduce friction, which helps relieve pain and prevents corns and calluses.
   • Taping or splinting the toe can hold it in a straighter position, temporarily correcting muscle imbalance and lessening irritation in shoes.
3. Orthotic devices and shoe inserts
   • Prefabricated or custom orthotic insoles support the arch and alter load distribution, reducing stress on the metatarsal region and toe joints
   • By improving foot biomechanics, orthotics may slow progression of the deformity, especially when hammer toe is associated with flat feet or other structural problems.
4. Exercises and stretching
   • Toe‑strengthening and stretching exercises are often prescribed when the toe is still flexible, such as picking up marbles with the toes or scrunching a towel, to improve intrinsic muscle balance.
   • Gentle manual stretches of the affected toe and calf‑muscle stretching can help reduce tendon tightness and maintain joint motion.
5. Medications and injections
   • Oral non‑steroidal anti‑inflammatory drugs (NSAIDs) can reduce pain and inflammation around the affected joints in symptomatic periods.
6. Skin and nail care
   • Regular debridement of corns and calluses by a podiatrist, combined with ongoing padding and proper footwear, reduces pain and risk of skin breakdown.
   • Patients at higher risk, such as those with diabetes or poor circulation, need careful monitoring to prevent ulcers over the prominent joints

Conservative care of hammer toes does not typically “reverse” an established deformity, but it often controls symptoms sufficiently that many patients avoid or delay surgery.

Indications for surgery

Surgery is considered when non‑surgical measures fail and the patient continues to have significant pain, difficulty wearing shoes, or functional limitations. Rigid toes that cannot be passively straightened, recurrent corns despite adequate footwear, and deformities causing ulceration are common indications.

Before surgery, clinicians assess:

• Flexibility of the toe (flexible vs fixed deformity).
• Condition of adjacent joints and overall foot alignment.
• Patient health, activity level, and expectations for recovery.

Most procedures are performed as day surgery with local or regional anesthesia.

Surgical techniques

The specific operation is tailored to the severity and rigidity of the toe deformity.

1. Soft‑tissue procedures (flexible hammer toes)
   • In flexible deformities, the main problem is often tendon and ligament imbalance, so operations aim to lengthen or transfer tendons without removing much bone.
   • Tendon lengthening reduces the excessive pull that keeps the toe bent, while tendon transfer (typically from the underside of the toe to the top) repositions the tendon so that it helps straighten and hold the toe down.
2. Bone procedures and joint resection (rigid hammer toes)
   • When the joint is stiff and fixed, surgeons may remove a small piece of bone from the proximal phalanx or the joint surfaces (arthroplasty) to allow the toe to straighten.nyp+3
   • In more severe deformities, the joint may be fused (arthrodesis) using pins, screws, or other implants, so the bone ends heal together into a single, straight segment that eliminates the painful motion.
3. Fixation and minimally invasive methods
   • Temporary pins are sometimes placed across the joint to maintain alignment while soft tissues and bone heal; they are usually removed after a few weeks once stability is achieved.
   • Some centres use key‑hole or minimally invasive techniques with small skin portals to cut bone and release soft tissues, aiming for less postoperative pain and swelling and quicker recovery.

Overall, the goal of surgery is to correct the deformity sufficiently to relieve pain and allow comfortable shoe wear, rather than to create a perfectly “normal‑looking” toe.mayoclinic+2

Postoperative care and outcomes

After hammer toe surgery, patients typically go home the same day in a protective shoe, with instructions to elevate the foot and limit weight‑bearing initially. Stitches and any external pins are removed after a short healing period, and patients gradually progress to normal footwear as swelling and tenderness settle, often over 4–6 weeks, with fuller return to all footwear and activities by around three months depending on the procedure.

Pain usually decreases significantly once healing has occurred, and most patients report improved shoe comfort and walking ability. However, there are recognised risks, including infection, stiffness, residual deformity, recurrence, or dissatisfaction with toe appearance, so careful patient selection and realistic preoperative counselling are essential. Even after surgery, ongoing attention to shoe choice and, where appropriate, orthotics and exercises remains important to protect the operated toe and prevent problems in adjacent toes.

Gout treatment focuses on rapidly controlling acute flares and preventing future attacks through long‑term urate lowering and lifestyle modification. Effective management requires matching therapy to comorbidities, using a treat‑to‑target serum urate strategy, and providing prophylaxis during urate‑lowering initiation.

Pathophysiological basis for treatment

Gout is an inflammatory arthritis caused by monosodium urate crystal deposition in and around joints, driven by sustained hyperuricaemia. When serum urate exceeds its solubility threshold, crystals form, triggering innate immune activation, particularly via NLRP3 inflammasome and interleukin‑1, and resulting in intense joint inflammation. Long‑standing hyperuricaemia leads to tophi, structural joint damage, and urate nephropathy, so treatment must both suppress inflammation and reduce the total body urate burden. This dual pathophysiological focus underpins the division of therapy into acute flare management and chronic urate‑lowering therapy.

Management of acute gout flares

Acute flares should be treated as early as possible, ideally within the first 24 hours of symptom onset, to shorten duration and reduce pain. First‑line options with broadly similar efficacy are non‑steroidal anti‑inflammatory drugs (NSAIDs), colchicine, and systemic or intra‑articular glucocorticoids, with the choice determined by comorbidities, contraindications, and patient preference

NSAIDs such as naproxen, indomethacin, or sulindac are effective when given at full anti‑inflammatory doses until at least one to two days after complete resolution of the flare. They are often avoided in patients with advanced renal impairment, peptic ulcer disease, heart failure, or significant cardiovascular disease, and gastroprotective strategies may be necessary in higher‑risk individuals. Colchicine, using modern low‑dose regimens (for example 1.2 mg followed by 0.6 mg one hour later, or 0.5–0.6 mg two to three times daily), offers similar pain relief to NSAIDs while reducing gastrointestinal toxicity compared with older high‑dose protocols. Dose reduction and careful monitoring are required in renal or hepatic impairment and when patients are taking interacting drugs such as certain macrolides or statins.

Systemic glucocorticoids, such as oral prednisolone 30–35 mg once daily for about five days, provide an alternative when NSAIDs and colchicine are contraindicated or not tolerated. Intra‑articular corticosteroid injection is particularly useful for monoarticular flares when septic arthritis has been excluded. Where standard therapies are unsuitable, interleukin‑1 blockade (for example anakinra) can be considered for refractory or complex flares, especially in the acute medical setting, although cost and availability limit use. Combining NSAIDs or glucocorticoids with colchicine may be necessary for very severe attacks, but concurrent use of oral NSAIDs and glucocorticoids is generally avoided because of increased gastrointestinal bleeding risk.

Urate‑lowering therapy and treat‑to‑target approach

Long‑term management aims to prevent further attacks, resolve tophi, and halt structural damage by achieving and maintaining target serum urate levels. Contemporary guidelines advocate a treat‑to‑target strategy: most patients should aim for serum urate below 360 µmol/L, with a more stringent target below 300 µmol/L in those with tophi, frequent flares, or severe chronic gouty arthropathy. Urate‑lowering therapy (ULT) is strongly recommended for patients with recurrent flares, tophi, urate nephrolithiasis, or radiographic damage, and many guidelines now support offering ULT earlier, including after a first flare in high‑risk individuals with very high urate or significant comorbidities.

Allopurinol, a xanthine oxidase inhibitor, is the preferred first‑line ULT for most patients because of its effectiveness, cost, and long experience of use. Standard practice is to “start low and go slow”, typically initiating at 50–100 mg daily (lower in advanced chronic kidney disease) and titrating every few weeks until the target serum urate is achieved. Screening for HLA‑B*5801 is recommended in some populations, particularly those of East Asian ancestry, because of the higher risk of allopurinol hypersensitivity syndrome in carriers. Febuxostat, another xanthine oxidase inhibitor, is an alternative when allopurinol is contraindicated, not tolerated, or insufficient at maximally tolerated doses; it reduces serum urate more effectively than standard‑dose allopurinol in many trials, including in patients with renal impairment.

Uricosuric agents, which enhance renal urate excretion, such as probenecid or benzbromarone (availability varies by jurisdiction), may be used as second‑line therapy or in combination with xanthine oxidase inhibitors for difficult‑to‑control disease. In severe, refractory tophaceous gout, intravenous pegylated uricase (for example pegloticase) offers rapid urate lowering and tophus resolution but is reserved for selected patients because of cost, infusion reactions, and the need for specialist supervision. Whatever agent is chosen, achieving and maintaining the serum urate target over the long term is more important than the specific drug, and lifelong therapy is often required.

Flare prophylaxis when starting ULT

Initiation of ULT can paradoxically precipitate gout flares as changing serum urate destabilises existing crystal deposits. To mitigate this, guidelines recommend concurrent prophylactic anti‑inflammatory therapy for at least three to six months after starting or escalating ULT. Low‑dose colchicine (for example 0.5–0.6 mg once or twice daily) is generally preferred where tolerated, with dose adjustment in renal or hepatic impairment and attention to drug interactions. Alternatives include low‑dose NSAIDs, such as naproxen 250–500 mg once or twice daily, or low‑dose prednisolone around 5 mg daily when colchicine and NSAIDs are unsuitable. Continuing prophylaxis until serum urate has been at target for several months reduces early flare burden and supports adherence to ULT.

Lifestyle and comorbidity management

Non‑pharmacological measures complement drug treatment but rarely suffice alone in established gout. Dietary advice typically emphasises limiting purine‑rich meats and seafood, reducing alcohol (especially beer and spirits), avoiding excess fructose‑sweetened beverages, and encouraging weight loss in people with obesity. Adequate hydration, choosing low‑fat dairy products, and increasing vegetable intake may help modestly lower serum urate and improve metabolic health. Optimising associated conditions such as hypertension, chronic kidney disease, diabetes, metabolic syndrome, and heart failure is essential, since these comorbidities both predispose to gout and influence the safety profile of gout medications.

Patient education and shared decision‑making are central to successful long‑term management. Explaining that gout is a chronic, curable crystal deposition disease rather than an inevitable consequence of ageing improves motivation for sustained urate‑lowering therapy. Structured follow‑up to monitor serum urate, assess adherence, adjust therapy, and reinforce lifestyle advice supports durable control and can ultimately lead to complete resolution of flares and tophi for many patients.

Heel lifts are commonly used in clinical practice to manage foot and ankle pain, particularly conditions affecting the plantar heel and Achilles tendon, but the evidence base is mixed and often low quality. They appear to offer short‑term pain relief and functional improvement in selected patients, while their long‑term efficacy and ideal prescription parameters remain uncertain.

Rationale and proposed mechanisms

Heel lifts elevate the calcaneus relative to the forefoot, effectively plantarflexing the ankle and altering load distribution through the foot and lower limb. By reducing peak ankle dorsiflexion and shortening the gastrocnemius–Achilles complex, heel lifts are thought to decrease tensile and compressive loads on painful tissues such as the plantar fascia and Achilles tendon insertion. Biomechanical studies in asymptomatic individuals demonstrate that heel lifts of 10–18 mm can reduce maximum ankle dorsiflexion angle, shorten gastrocnemius–tendon unit length during running, and modify muscle activation patterns, supporting a mechanical basis for symptom change. In addition, elevating the heel can redistribute plantar pressures away from the posterior calcaneus, which may be particularly relevant in plantar heel pain and calcaneal spur–related discomfort.

Evidence in plantar heel pain

Several clinical and quasi‑experimental studies have evaluated heel elevation or heel lifts in plantar heel pain, though most are small and at high risk of bias. A systematic review of heel lifts for lower limb musculoskeletal conditions found very low‑certainty evidence from a single trial (n = 62) that heel lifts improved pain and function more than indomethacin at 12 months in plantar heel pain, as measured by the Foot Function Index. Another trial in calcaneal apophysitis suggested that custom orthoses were superior to simple heel lifts for pain relief at 12 weeks, indicating that a heel lift alone may be less effective than more comprehensive orthotic interventions in some paediatric presentations. Outside formal trials, a small study of patients with radiographic heel spurs showed that increasing shoe heel height reduced plantar heel pain in most individuals over eight weeks, with optimal relief at heel heights of 3–4 cm, presumably by lowering plantar forces under the calcaneus.

These findings suggest that heel lifts can reduce plantar heel pain for some patients, but they also highlight heterogeneity in response and the importance of individual foot morphology. For example, work by Kogler and colleagues (summarised in a narrative review) indicates that arch configuration may influence how heel elevation affects plantar fascia strain, implying that some arch types may benefit more from this strategy than others. Clinically, this supports using heel lifts as part of a broader management plan that may include stretching, load management, strengthening, and, where indicated, custom foot orthoses, rather than as a stand‑alone cure.

Use in Achilles tendinopathy

Heel lifts are widely advocated in Achilles tendinopathy due to their capacity to reduce dorsiflexion range and potentially decrease tendon loading during walking and running. A systematic review of heel lifts reported low‑ to moderate‑certainty evidence that, in at least one trial of mid‑portion Achilles tendinopathy, heel lifts were superior to eccentric calf exercise alone in reducing pain severity and improving VISA‑A scores at 12 weeks, with similar rates of minor adverse events such as new areas of musculoskeletal pain or blisters. More recent work in insertional Achilles tendinopathy has reinforced this potential benefit: a prospective study showed immediate reduction in pain during gait and improvement in symptom severity after two weeks of using in‑shoe heel lifts, along with positive changes in gait parameters such as walking speed and stride length. Biomechanically, these effects may relate to increased distance between the tendon and calcaneus in static stance and altered stance‑phase sub‑phase timing, including increased load response and decreased preswing duration.

Randomised feasibility work, such as the LIFTIT trial for insertional Achilles tendinopathy, indicates that a fully powered trial comparing heel lifts with sham devices is feasible and that preliminary data “signal” improvements in pain, function, physical activity, and quality of life with heel lifts. However, these pilot studies are not powered to definitively establish efficacy, and planned large‑scale trials like the LIFT trial for mid‑portion Achilles tendinopathy are still underway or recently initiated. Thus, while clinical and early trial evidence support the short‑term use of heel lifts as part of conservative care for Achilles tendinopathy, there is still uncertainty about optimal lift height, duration of use, and comparative effectiveness against other evidence‑based treatments such as heavy–slow resistance programs.

Broader biomechanical and clinical considerations

Beyond plantar heel pain and Achilles tendinopathy, heel lifts can influence global lower limb biomechanics, which has potential benefits and risks. Studies have shown that heel elevation during walking, running, or squatting can reduce ankle dorsiflexion demands, increase ankle work contribution, and modify activation of key muscles including the gastrocnemius, vastus lateralis, biceps femoris, and tibialis anterior. These changes may help clinicians offload painful structures, facilitate certain rehabilitation exercises, or accommodate limited ankle dorsiflexion in patients with equinus or post‑surgical stiffness. On the other hand, narrative reviews caution that higher heel elevations—whether via lifts or high‑heeled footwear—can alter gait patterns, increase fall and inversion sprain risk, and shift plantar pressure to the forefoot, potentially provoking new symptoms in the forefoot, knee, hip, or lumbar spine.

In addition, heel lifts may trigger neuromuscular responses that increase calf muscle activity, which is not uniformly beneficial; in some individuals this might aggravate posterior chain symptoms rather than relieve them. Adverse events reported in trials include development of new pain in the lower back, hips, knees, feet, or ankles, as well as skin irritation and blisters, although overall rates appear similar to comparison interventions. These findings underline the importance of careful patient selection, gradual introduction, and close monitoring when using heel lifts, particularly in individuals with complex multi‑site pain or balance impairments.

Clinical application and future directions

In practice, heel lifts are best viewed as a supportive adjunct rather than a definitive treatment for foot pain. For plantar heel pain, a modest, removable heel lift can be trialled alongside education, activity modification, plantar fascia–focused strengthening, and calf stretching, with close attention to changes in pain, function, and plantar pressure distribution. For mid‑portion and insertional Achilles tendinopathy, heel lifts may be particularly useful in the early, irritable phase to reduce pain during gait and exercise, potentially improving adherence to progressive loading programs. Clinicians should individualise lift height, usually starting with small increments (for example 6–10 mm) and adjusting based on symptom response and gait observation, while monitoring for secondary issues such as forefoot overload.

From a research perspective, the current literature is characterised by small samples, heterogeneous protocols, and low‑certainty evidence, despite promising signals of benefit in specific conditions. Ongoing and future randomised controlled trials comparing heel lifts with sham devices, custom orthoses, and established exercise programs will be critical to defining their true clinical value, cost‑effectiveness, and ideal prescription parameters. Until then, heel lifts should be prescribed judiciously, with clear expectations communicated to patients that they are one component of a multimodal strategy aimed at reducing pain, optimising load, and facilitating return to function rather than a stand‑alone cure.

Foot orthotics are widely used medical devices designed to support, align, and improve the function of the foot and lower limb. They play an important role in managing pain, optimising biomechanics, and preventing injury across a range of patient populations, from high‑performance athletes to people with chronic disease.

Definition and Types of Foot Orthotics

Foot orthotics (or foot orthoses) are external devices placed inside footwear to modify the mechanical function of the foot and lower limb. They are typically used to support arches, redistribute plantar pressures, and influence joint motion throughout the kinetic chain.

Broadly, orthotics are classified as:

• Prefabricated (off‑the‑shelf) devices, manufactured to generic foot shapes and conditions.
• Custom‑made devices, fabricated from a 3D representation of an individual’s foot (plaster, foam, or digital scan) and prescribed after a biomechanical assessment.

They can also be described by function: accommodative orthoses, made from softer materials to cushion and relieve pressure; and functional orthoses, often more rigid or semi‑rigid, aimed at controlling motion, particularly excessive pronation or supination. This basic taxonomy underpins clinical decision‑making when matching device type to pathology and patient goals.

Biomechanical Rationale and Mechanisms of Action

The use of foot orthotics rests on the principle that altering foot–ground interaction can change forces and motion throughout the lower limb. Orthoses can redistribute plantar pressure away from painful or high‑risk areas, such as metatarsal heads or the medial heel, by increasing contact area and supporting the longitudinal and transverse arches.

By contouring to the plantar surface and incorporating posting or wedging, orthotics can influence rearfoot and forefoot position in stance and gait. Controlling excessive pronation, for example, can reduce internal tibial rotation and downstream stresses at the knee and hip, while improving alignment may lessen compensatory muscle activity and fatigue. In addition, materials with shock‑absorbing properties attenuate impact forces during walking and running, which can reduce repetitive loading on bones, joints, and soft tissues.

Clinical Indications and Therapeutic Benefits

Foot orthotics are prescribed for a wide range of musculoskeletal and systemic conditions affecting the feet and lower limbs. Common indications include plantar fasciitis, posterior tibial tendon dysfunction, metatarsalgia, and mechanical heel pain, where orthoses help offload symptomatic tissues and support strained structures. They are also used in patients with flat feet or high arches to improve stability, distribute pressure more evenly, and reduce localised discomfort.

Beyond local foot pathology, orthoses may assist in managing shin splints, patellofemoral pain, and some presentations of knee, hip, or lower back pain when these are driven or exacerbated by abnormal foot mechanics. In people with diabetes or peripheral neuropathy, accommodative orthotics and total‑contact insoles are integral to ulcer prevention strategies because they reduce peak plantar pressures and shear in high‑risk areas. In the athletic population, orthotics are employed both as a treatment and as a preventive measure, with evidence suggesting reductions in overuse injuries and stress fractures in certain sporting cohorts.

Role in Performance, Function, and Quality of Life

Although their primary purpose is therapeutic, foot orthotics can also contribute to improved functional performance. By optimising alignment and enhancing stability, they may facilitate more efficient gait and running mechanics, allowing improved propulsion and reduced perceived exertion in some individuals. Enhanced shock absorption and pressure distribution can translate to greater comfort during prolonged standing, walking, or sport, which indirectly supports performance by delaying fatigue.

Importantly, orthotics can have a substantial impact on quality of life. For people whose activity is limited by chronic foot or lower limb pain, an effective orthotic prescription can restore the capacity to work, exercise, and participate in daily tasks. In older adults, improved stability and balance from appropriate footwear and orthoses may reduce fall risk and increase confidence in mobility. These functional gains underscore the broader health value of orthotic therapy beyond local symptom relief.

Limitations, Risks, and Considerations in Prescription

Despite their benefits, foot orthotics are not a universal solution and must be prescribed judiciously. Poorly indicated or poorly fitted devices can provoke new symptoms, such as pressure lesions, altered gait patterns, or pain elsewhere in the kinetic chain. Patients may also experience an adaptation period with transient discomfort as tissues adjust to altered loading.

Cost is a relevant limitation, especially for custom devices, and can affect adherence. Moreover, orthotics should rarely be used in isolation. Best‑practice management typically integrates them with footwear modification, targeted exercise therapy, load management, and, when appropriate, weight management or workplace changes. Long‑term or repeated use without periodic review may be problematic, as materials wear, patient biomechanics change, and underlying conditions evolve. Regular reassessment helps determine whether the device is still necessary, needs modification, or can be weaned.

Conclusion

The use of foot orthotics represents a key conservative intervention in contemporary lower‑limb care. By modifying foot function and load distribution, orthoses can relieve pain, prevent injury, and support better movement across diverse patient groups. Their effectiveness, however, depends on careful assessment, appropriate device selection, and integration into a broader, evidence‑based treatment plan that considers the whole person rather than the foot in isolation

Foot manipulation is a broad term encompassing joint mobilisation, high‑velocity manipulative thrusts, and soft‑tissue techniques applied to the foot and ankle to relieve pain and improve function. Within contemporary foot care, these interventions sit alongside exercise, taping, orthoses and footwear modification rather than replacing them, and the evidence suggests that their benefits are often adjunctive and condition‑specific rather than universally transformative.

Concepts and mechanisms

Foot manipulation and mobilisation target the numerous synovial joints of the foot and ankle, including the talocrural, subtalar, midtarsal and tarsometatarsal articulations. Techniques may involve low‑grade oscillatory glides, end‑range mobilisation with movement, or high‑velocity, low‑amplitude (HVLA) thrusts intended to overcome perceived joint restriction and reposition articular surfaces.

The proposed mechanisms of pain relief include:

• Mechanical effects, such as restoring joint play, reducing positional faults (for example at the calcaneocuboid joint), and improving load distribution across plantar soft tissues.
• Neurophysiological effects, in which rapid or sustained joint and soft‑tissue input modulates nociceptive processing and muscle tone, producing immediate but sometimes transient reductions in pain.
• Indirect biomechanical changes, including improved dorsiflexion or midfoot mobility that may reduce tensile and compressive stresses on structures such as the plantar fascia or tibialis posterior tendon.

Evidence in plantar heel pain

Plantar fasciitis, or plantar heel pain, is one of the most frequently studied conditions in relation to manual therapy of the foot. A randomized study comparing three protocols—foot and ankle manipulation plus cross‑friction massage, stretching of the gastroc‑soleus complex plus cross‑friction massage, and a combination of all three—found that all groups experienced meaningful reductions in pain and disability and improved ankle dorsiflexion. In that trial, stretching plus cross‑friction massage produced the greatest overall improvement in pain and function, while protocols that included manipulation produced larger gains in plantarflexion range.

Another single‑blind randomized controlled trial examined the effect of adding ankle, subtalar and midfoot mobilisations to a standard regimen of stretching and therapeutic ultrasound in patients with plantar fasciitis. Both groups improved in pain scores and function, but there was no statistically or clinically significant additional benefit from the joint mobilisation component, suggesting that for many patients soft‑tissue and exercise interventions may be sufficient.

Myofascial and trigger‑point manual therapy directed at muscles associated with plantar heel pain (such as gastrocnemius, soleus and intrinsic foot muscles) has also been studied. In one trial, the addition of specific trigger‑point manual therapies to a self‑stretching protocol yielded superior short‑term reductions in pain and better improvements in physical function when compared with stretching alone, with effect sizes that exceeded accepted minimal clinically important differences. Collectively, these findings suggest that while joint manipulation per se may not always outperform conventional care, targeted manual therapy—especially when combined with stretching—can enhance outcomes in plantar heel pain

Cuboid syndrome and midfoot pain

Cuboid syndrome, often described as a subtle subluxation or loss of congruity at the calcaneocuboid joint, represents one of the clearest indications where cuboid manipulation is regarded as a primary intervention. It typically follows an inversion–plantarflexion injury or repetitive overload and presents with lateral midfoot pain, tenderness over the cuboid, and pain on push‑off.

Manual techniques such as the “cuboid whip” and “cuboid squeeze” are designed to rapidly restore the calcaneocuboid relationship. Case‑based literature and critical appraisals report that many patients experience immediate and substantial relief after successful cuboid manipulation, sometimes returning to sport the same day in acute cases. In a case report of posterior tibialis tendinopathy associated with cuboid mobility restriction, a single cuboid whip manipulation normalized midtarsal pronation and reduced pain to 0/10 immediately, far surpassing the partial relief obtained from prior soft‑tissue work, stretching and taping.

However, symptom duration appears to influence response: reviews note that patients with cuboid syndrome present for a month may need several manipulations, and chronic cases of more than six months’ duration may require months of combined care despite immediate partial improvement after each manipulation. Current appraisals emphasise that high‑quality randomized trials are lacking, but support manipulation as part of a conservative package alongside rest, strengthening, padding and taping, with surgery reserved for rare refractory presentations.

Foot mobilisation therapy in practice

Beyond distinct syndromes, some practitioners employ broader Foot Mobilisation Therapy (FMT) or similar frameworks aimed at systematically mobilising multiple foot and ankle joints to restore what is described as normal joint function and range. Such approaches are commonly marketed for chronic, non‑specific foot pain, stiffness, or recurring overuse injuries, with the rationale that improving joint mobility and alignment can reduce compensatory stresses throughout the kinetic chain.

Evidence directly evaluating global foot mobilisation protocols is limited and heterogeneous, often consisting of clinical experience, case series and small trials rather than large, definitive randomized studies. Nonetheless, clinical reports and practitioner‑level syntheses highlight improvements in dorsiflexion, symptom severity and gait comfort in conditions such as subacute ankle sprains when Mulligan‑style mobilisation with movement is applied, reinforcing the concept that joint‑directed manual therapy can be a useful adjunct in selected musculoskeletal presentations.

Clinical integration and limitations

Across conditions, a consistent theme is that manipulation and manual therapy are most effective when integrated into a multimodal management plan rather than used in isolation. Typical adjuncts include stretching of the gastrocnemius–soleus complex and plantar fascia, intrinsic and extrinsic muscle strengthening, taping, orthotic or footwear modification, load management and patient education. In plantar heel pain and many overuse conditions, high‑quality studies show that exercise and soft‑tissue strategies alone can produce substantial benefit, with manipulation adding little or only short‑term change for some patients.

There are also clear limitations to what manipulation can achieve. Structural deformities, advanced degenerative changes, inflammatory arthropathies and neuropathic pain will not be “corrected” by joint manipulation, and inappropriate or repeated thrust techniques in the presence of instability, fracture, severe osteoporosis or vascular compromise may be harmful. For these reasons, current expert opinion stresses careful differential diagnosis, awareness of red flags, and the need to reserve manipulative procedures for clearly indicated mechanical dysfunctions, with informed consent and conservative dosing.

In summary, foot manipulation occupies a nuanced role in the treatment of foot pain: it can provide rapid and sometimes dramatic relief in specific mechanical syndromes such as cuboid syndrome, and it may enhance short‑term outcomes when combined with stretching and soft‑tissue work in plantar heel pain. Yet, for many common foot conditions, the best outcomes arise from a broader, evidence‑informed programme in which manual therapy is one tool among many, tailored to the individual’s pathology, biomechanics and functional goals rather than applied as a stand‑alone cure.

Forefoot supinatus is an acquired, soft-tissue–based deformity in which the forefoot becomes held in an inverted (supinated) position relative to the rearfoot, usually as a compensation to excessive pronation and flatfoot mechanics. It is flexible or reducible in its early stages, can mimic true forefoot varus, and plays an important role in the development and persistence of abnormal gait, pain, and overuse injury in the lower limb. Understanding its definition, biomechanics, differentiation from structural deformities, clinical features, and treatment options is essential for accurate diagnosis and effective management in podiatry and musculoskeletal practice.

Definition and biomechanics

Forefoot supinatus is defined as an acquired soft tissue contracture that holds the forefoot in a supinated or inverted position about the joints of the midfoot, rather than a fixed bony malalignment. In this condition, the medial column (first ray and adjacent structures) tends to be dorsiflexed and inverted relative to the rearfoot, producing an apparent forefoot varus when the subtalar joint is placed in neutral.

Biomechanically, the deformity develops as an adaptive response to chronic pronation of the subtalar and midtarsal joints, particularly in adult acquired flatfoot. Excessive calcaneal eversion forces the midtarsal joint to supinate about its longitudinal axis and often dorsiflexes the first ray, so that over time the soft tissues adapt and hold the forefoot in an inverted position even when the pathologic forces are reduced.

Aetiology and pathogenesis

Forefoot supinatus arises secondarily to pathological forces that either dorsiflex the medial metatarsals or prevent their plantarflexion during gait. Two major mechanisms are commonly highlighted: ankle equinus (limited ankle dorsiflexion) and excessive subtalar joint pronation, both of which increase forefoot loading in a way that promotes inversion and soft tissue contracture of the medial column.

With excessive calcaneal eversion, the forefoot is forced to invert about the midtarsal longitudinal axis to maintain contact with the ground, and the medial column dorsiflexes and becomes hypermobile. Over time, this repeated compensation leads to adaptive shortening of capsular and ligamentous structures, so that the inverted forefoot position becomes semi-fixed; according to Davis’s law, soft tissues remodel in response to chronic mechanical stress, reinforcing the acquired deformity.

Distinction from forefoot varus

Forefoot supinatus is often confused with forefoot varus, yet the two have different origins and clinical implications. Forefoot varus is classically described as a congenital, osseous deformity in which the forefoot is structurally inverted relative to the rearfoot when the subtalar joint is neutral, thereby inducing subtalar pronation to bring the medial forefoot to the ground.

By contrast, forefoot supinatus is an acquired, soft-tissue deformity that develops because of subtalar joint pronation rather than causing it, meaning it is a result rather than a primary driver of overpronation. A practical distinction is that supinatus is typically reducible—manual plantarflexion of the medial column can correct the apparent varus—whereas a true forefoot varus remains inverted even when soft tissues are stretched, reflecting its bony origin.

Clinical presentation and assessment

Clinically, patients with forefoot supinatus frequently present in the context of flatfoot deformity, overpronation, or adult acquired flatfoot, often accompanied by medial arch collapse and calcaneal eversion. Symptoms can include plantar fasciitis, metatarsalgia, callus formation under the metatarsal heads, and proximal overuse problems such as shin splints or knee and hip pain associated with altered pronation–supination mechanics.

On examination, the forefoot appears inverted relative to the rearfoot in subtalar neutral, but this inversion can often be reduced by manually plantarflexing the first ray and medial column, revealing the flexible nature of the deformity. Specific clinical tests, sometimes referred to as supinatus–varus tests, are used to differentiate supinatus from structural forefoot varus, as misclassification can lead to inappropriate orthotic posting and worsening of midfoot stress.

Management and clinical significance

Management of forefoot supinatus focuses on addressing the underlying biomechanical causes while gradually reducing the soft tissue contracture of the medial column. Treatment strategies may include calf stretching for equinus, strengthening and neuromuscular training of the intrinsic and extrinsic foot muscles, and carefully designed orthoses that avoid excessive medial forefoot posting in a reducible supinatus deformity.

If a supinatus deformity is treated as a fixed forefoot varus with rigid medial forefoot posting, abnormal stresses can occur at the first tarsometatarsal joint and along the medial column, potentially leading to pain, exostosis, and further dysfunction. Recognising forefoot supinatus as an acquired, potentially reversible soft-tissue adaptation enables more conservative, tissue-friendly interventions and may improve outcomes for patients with flatfoot-related pain and overuse injuries.

Fibromyalgia often causes pain, stiffness, and abnormal sensitivity in the feet, which can make standing, walking, and wearing shoes unusually difficult and exhausting. These foot symptoms can significantly limit mobility and reduce quality of life for many people living with this condition.

What fibromyalgia is

Fibromyalgia is a long‑term pain condition in which the nervous system becomes unusually sensitive and amplifies pain signals from the body. Instead of acting as a normal filter, the brain and spinal cord overreact to touch, pressure, movement, and even temperature, so sensations that would not normally hurt can become painful.

Beyond pain, fibromyalgia is linked with fatigue, non‑restorative sleep, and problems with concentration, all of which can worsen the experience of foot pain and make day‑to‑day activities harder.

How it affects foot tissues

Fibromyalgia does not damage bones or joints directly, but it can affect muscles, ligaments, fascia, and nerves in the feet. Muscles that support the arch and control the toes may become tense and tender, while ligaments and fascia, such as the plantar fascia along the sole, can feel tight or sore, especially with prolonged standing. Nerve fibers in the feet may also become hypersensitive, sending stronger pain messages than normal when they are compressed by shoes or stressed by walking.

Some people with fibromyalgia also have structural or biomechanical issues, such as flat feet, high arches, or over‑pronation, which can interact with the sensitized nervous system and further increase foot discomfort. When the arch collapses or the foot rolls inward, pressure shifts to different areas of the sole, and in fibromyalgia even these normal mechanical stresses can be perceived as intense pain.

Symptoms in the feet

Studies suggest that roughly half of people with fibromyalgia report pain in one or both feet, much more often than in people without the condition. Foot pain may be described as burning, aching, stabbing, throbbing, or a sensation like walking on bruises or pebbles, and it often affects the soles, heels, sides, or tops of the feet. Many people notice that the first steps in the morning or after sitting feel especially painful or stiff, and even light pressure from socks or shoe uppers can be uncomfortable because of heightened sensitivity.

In addition to pain, there can be tingling, numbness, or “pins and needles,” which reflect nerve involvement or co‑existing conditions such as small‑fiber neuropathy. Tender points or trigger points in the feet—small, very sensitive spots in muscles or fascia—may cause sharp localized pain when pressed and can refer discomfort along the arch or into the toes. Stiffness in the small joints and soft tissues can make the feet feel wooden or inflexible, particularly after rest.

Effects on walking and daily life

Because the feet bear body weight with every step, fibromyalgia‑related foot pain often changes the way a person walks. Research shows that people with fibromyalgia tend to walk more slowly and take shorter steps, which may be a protective response to pain in the soles and ankles. This altered gait can in turn strain the knees, hips, and lower back, adding new areas of discomfort and contributing to overall physical deconditioning.

Everyday activities that rely on standing or walking can become draining or feel nearly impossible on bad days. Tasks such as grocery shopping, work that requires prolonged standing, or social events that involve walking long distances may be limited or avoided, which reduces participation in work, exercise, and leisure and often worsens mood and sleep.

Management and support

Managing fibromyalgia‑related foot problems usually involves a mix of nervous‑system‑focused treatments and practical foot care strategies. Approaches may include gentle physical therapy, stretching of the calf and plantar fascia, supportive footwear or custom orthotics to improve alignment, and pacing activities to prevent overloading the feet. Some people also benefit from medications used in fibromyalgia, such as those that calm nerve activity, alongside local measures like ice or heat, soft insoles, and targeted work on trigger points.

Addressing sleep, stress, and general fitness is important, because poor sleep and high stress can increase pain sensitivity and make foot symptoms feel more severe. Education about why the feet hurt in fibromyalgia can reduce fear and help people choose supportive habits—such as regular low‑impact movement and comfortable, properly fitted shoes—that protect the feet while still keeping them as active as possible.